Mission Therapeutics is pairing MTX325, a brain-penetrant inhibitor of the enzyme USP30 that restrains mitochondrial clearance, with NeuraLight's AI-based eye-tracking platform in a Phase Ib Parkinson's trial across the UK, Europe and Australia. The drug aims to restore mitophagy in dopamine-producing neurons, while oculometric measurement replaces observer-scored rating scales as a sensitive readout of neural function. Mitochondrial decline is a recurring driver of age-related deterioration beyond the brain, making both the mechanism and the measurement method relevant to aging research broadly.
Key Points
- MTX325 blocks USP30 to restore stalled mitochondrial clearance in neurons
- Eye-movement tracking replaces subjective clinical rating scales as endpoint
- Phase Ia confirmed brain penetration via spinal fluid and imaging
Longevity Analysis
Accumulation of damaged mitochondria links Parkinson's to heart failure, sarcopenia and frailty, which positions restored cellular clearance as an intervention with reach far beyond dopaminergic neurons. The measurement side matters equally: oculometric tracking captures degradation in neural circuits earlier and more reproducibly than a clinician's scored observation, shifting neurodegeneration from something noticed once symptoms declare themselves to something quantified while function is still largely intact. Objective, repeatable signals of how well the brain is producing energy and disposing of its own waste are what turn slow decline into a tractable target.
Original published by Longevity.Technology, by Kyle Umipig.